Interrogation of PI3K inhibition strategies in non-small cell lung cancer (NSCLC)

Abstract

Lung cancer is the leading cause of cancer related death in Ireland and much of the Western world. Despite advances in anti-cancer therapies, the overall 5 year survival for lung cancer remains poor, at less than 15%. As such it is crucial that we determine new strategies to overcome this formidable disease. Non-small cell lung cancer (NSCLC) refers to all histological subtypes of lung cancer other than small cell lung cancer, and accounts for -80% of lung cancers. PI3K signalling can induce all eight hallmarks of cancer in NSCLC and other cancers, and as such a plethora of PI3K targeted inhibitors have been developed in recent years with a view to halting oncogenic signalling in cancer cells.